Etanercept for Alzheimer's-Type Memory Loss Pilot Study

Tobinick, Edward Lewis, M.D.1 site in 1 country15 target enrollmentSeptember 2004

ConditionsAlzheimer's Disease

Drugsetanercept given by perispinal administration

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Alzheimer's Disease
Sponsor: Tobinick, Edward Lewis, M.D.
Enrollment: 15
Locations: 1
Primary Endpoint: MMSE
Status: Completed
Last Updated: 20 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.

Detailed Description

Etanercept, a biologic anti-TNF fusion protein, will be administered weekly or biweekly by perispinal injection to a maximum of 15 study subjects for a period of one month, followed by a 5 month and a 6 month possible study extension, with serial testing of cognition and function monthly.

Registry

clinicaltrials.gov

Start Date

September 2004

End Date

April 2006

Last Updated

20 years ago

Study Type

Interventional

Study Design

Single Group